Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2016-03-08 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Purchase of 3000 ordinary shares) made by a person in a managerial position ("Gerhard Roggemann, Member of an administrative or supervisory body"). This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2016-03-08 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing changes in voting rights percentages (crossing thresholds on 02 March 2016) held by BlackRock, Inc. in Fresenius SE & Co. KGaA, referencing German Securities Trading Act (WpHG) sections. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although it mentions 'Voting Rights Announcements' in the header, the content is a detailed disclosure of shareholding changes, fitting MRQ better than DVA (which is for voting results) or RNS (which is a fallback).
2016-03-08 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information about a transaction made by a person in a managerial role ('Krick, Gerd, Position: Member of an administrative or supervisory body'). It follows the structure of a mandatory disclosure regarding insider trading or transactions by management, which aligns perfectly with the definition for Director's Dealing (DIRS). The reference to 'section 15a of the WpHG' further confirms this regulatory context.
2016-03-07 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in major shareholdings ('Notification of Major Holdings') by BlackRock, Inc. in Fresenius SE & Co. KGaA, referencing German Securities Trading Act (WpHG) sections. This type of filing, which reports changes in ownership thresholds by major shareholders, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a detailed disclosure of voting rights percentage changes, which is the core function of an MRQ filing.
2016-03-03 English
Roadshow New York
Investor Presentation Classification · 98% confidence The document text contains extensive financial data, segment breakdowns (Fresenius Medical Care, Kabi, Helios, Vamed), FY/15 results, 2016 outlooks, mid-term targets (FY 2019), and detailed Profit and Loss statements. It is explicitly titled as a 'Roadshow New York – March 3, 2016' presentation, which is a common format for presenting detailed financial and strategic information to investors. This structure strongly indicates an Investor Presentation (IP). It is too detailed to be a simple Earnings Release (ER) or a short Fund Factsheet (FS). Since it is a presentation deck, IP is the most appropriate classification.
2016-03-03 English
Roadshow Boston
Investor Presentation Classification · 98% confidence The document is titled 'Roadshow Boston – March 2, 2016' and contains extensive slides detailing the company's business segments (Fresenius Medical Care, Kabi, Helios, Vamed), financial results for FY/2015 and Q4/2015, growth outlooks for 2016, and mid-term targets (FY 2019). This structure, combining strategic overview, operational details, and financial performance presentation, is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER) or a transcript (CT). The presence of 'ATTACHMENTS' and detailed tables suggests a comprehensive presentation deck.
2016-03-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.